Skip to main content
SpringerLink
Log in

68Ga-labelled peptides in the management of neuroectodermal tumours

  • Review Article
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

Abstract

Neuroectodermal tumours arise from chromaffin cells and possess the ability to secrete catecholamines. They are generally rare and may occur in association with a variety of hereditary syndromes such as MEN-2A and 2B, neurofibromatosis type 1 and von Hippel-Lindau disease. The most common types are phaeochromocytoma arising from the adrenal medulla and paraganglioma of extra-adrenal origin. Phaeochromocytomas tend to be benign and are often associated with a gene mutation if the disease is bilateral, while paragangliomas are often malignant, have a more aggressive nature and tend to metastasize. There are no specific histological or immunohistochemical features that indicate the malignant potential and the diagnosis of malignancy can only be established by the presence of distant metastases. Therefore, imaging can play a vital role in the diagnosis, localization, staging and assessment of spread. Traditionally, this is achieved with a combination of cross-sectional (CT and MRI) and functional (123I-MIBG or 111In-octreotide) imaging. However, these modalities are not adequate and achieve moderate sensitivity. The introduction of 68Ga-DOTA peptide in PET/CT imaging has led to improved receptor targeting and superb PET resolution, as well as accurate localization of lesions. The use of this technique in neuroectodermal tumours has been shown to be superior to all available modalities, but the available data are limited and larger studies are awaited to establish its role in the management of these tumours.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Baysal BE. Hereditary paraganglioma targets diverse paraganglia. J Med Genet. 2002;39:617–22.

    Article  PubMed  CAS  Google Scholar 

  2. Neumann HP, Bausch B, McWhinney SR, Bender BU, Gimm O, Franke G, et al. Germline mutations in nonsyndromic pheochromocytoma. N Eng J Med. 2002;346:1459–66.

    Article  CAS  Google Scholar 

  3. Lenders JW, Eisenhofer G, Mannelli M, Pacak K. Phaeochromocytoma. Lancet. 2005;366:665–75.

    Article  PubMed  Google Scholar 

  4. Baysal BE, Ferell RE, Willet-Brozick JE, Lawrence EC, Myssiorek D, Bosch A, et al. Mutations in SDHD, a mitochondrial complex II gene, in hereditary paragangliomas. Science. 2000;287:848–51.

    Article  PubMed  CAS  Google Scholar 

  5. Boedeker CC, Ridder GJ, Schipper J. Paragangliomas of the head and neck: diagnosis and treatment. Fam Cancer. 2005;4:55–9.

    Article  PubMed  CAS  Google Scholar 

  6. Persky MS, Setton A, Niimi Y, Hartman J, Frank D, Berenstein A. Combined endovascular and surgical treatment of head and neck paragangliomas: a team approach. Head Neck. 2002;24:423–31.

    Article  PubMed  Google Scholar 

  7. Ilias I, Pacak K. Current approaches and recommended algorithm for the diagnostic localization of pheochromocytoma. J Clin Endocrinol Metab. 2004;89:479–91.

    Article  PubMed  CAS  Google Scholar 

  8. Maurea S, Cuocolo A, Reynolds JC, Tumeh SS, Begley MG, Linehan WM, et al. Iodine-131-metaiodobenzylguanidine scintigraphy in preoperative and postoperative evaluation of paragangliomas: comparison with CT and MRI. J Nucl Med. 1993;34:173–9.

    PubMed  CAS  Google Scholar 

  9. Go AS. Refining probability: an introduction to the use of diagnostic tests. In: Friedland DJ, editor. Evidence-based medicine. New York: McGraw-Hill; 1998. p. 12–33.

    Google Scholar 

  10. Schulz C, Eisenhofer G, Lehnert H. Principles of catecholamine biosynthesis, metabolism and release. Front Horm Res. 2004;31:1–25.

    Article  PubMed  CAS  Google Scholar 

  11. Bomanji J, Levison DA, Flatman WD, Horne T, Bouloux PM, Ross G, et al. Uptake of iodine-123 MIBG by pheochromocytomas, paragangliomas, and neuroblastomas: a histopathological comparison. J Nucl Med. 1987;28:973–8.

    PubMed  CAS  Google Scholar 

  12. Furuta N, Kiyota H, Yoshigoe F, Hasegawa N, Ohishi Y. Diagnosis of pheochromocytoma using [123I]- compared with [131I]-metaiodobenzylguanidine scintigraphy. Int J Urol. 1999;6:119–24.

    Article  PubMed  CAS  Google Scholar 

  13. Shulkin BL, Ilias I, Sisson JC, Pacak K. Current trends in functional imaging of pheochromocytomas and paragangliomas. Ann N Y Acad Sci. 2006;1073:374–82.

    Article  PubMed  Google Scholar 

  14. Berglund AS, Hulthen UL, Manhem P, Thorsson O, Wollmer P, Törnquist C, et al. Metaiodobenzylguanidine (MIBG) scintigraphy and computed tomography (CT) in clinical practice. Primary and secondary evaluation for localization of phaeochromocytomas. J Intern Med. 2001;249:247–51.

    Article  PubMed  CAS  Google Scholar 

  15. Mann GN, Link JM, Pham P, Pickett CA, Byrd DR, Kinahan PE, et al. [11C]metahydroxyephedrine and [18F]fluorodeoxyglucose positron emission tomography improve clinical decision making in suspected pheochromocytoma. Ann Surg Oncol. 2006;13(2):187–97.

    Article  PubMed  Google Scholar 

  16. Kwekkeboom D, van Urk H, Pauw KH, Lamberts SW, Kooij PP, Hoogma RP, et al. Octreotide scintigraphy for the detection of paraganglioma. J Nucl Med. 1993;34:873–8.

    PubMed  CAS  Google Scholar 

  17. van der Harst E, de Herder WW, Bruining HA, Bonjer HJ, de Krijger RR, Lamberts SW, et al. [(123)I]metaiodobenzylguanidine and [(111)In]octreotide uptake in benign and malignant pheochromocytomas. J Clin Endocrinol Metab. 2001;86:685–93.

    Article  PubMed  Google Scholar 

  18. Koopmans KP, Jager PL, Kema IP, Kerstens MN, Albersy F, Dullaart RP. 111In-octreotide is superior to 123I-metaiodobenzylguanidine for scintigraphic detection of head and neck paragangliomas. J Nucl Med. 2008;49:1232–7.

    Article  PubMed  Google Scholar 

  19. Bombardieri E, Seregni E, Villano C, Chiti A, Bajetta E. Position of nuclear medicine techniques in the diagnostic work-up of neuroendocrine tumors. Q J Nucl Med Mol Imaging. 2004;48:150–63.

    PubMed  CAS  Google Scholar 

  20. Ueberberg B, Tourne H, Redman A, Walz MK, Schmid KW, Mann K, et al. Differential expression of the human somatostatin receptor subtypes sst1 to sst5 in various adrenal tumours and normal adrenal gland. Horm Metab Res. 2005;37:722–8.

    Article  PubMed  CAS  Google Scholar 

  21. Neumann DR, Basile KE, Bravo EL, Chen EQ, Go RT. Malignant pheochromocytoma of the anterior mediastinum: PET findings with [18F]FDG and 82Rb. J Comput Assist Tomogr. 1996;20:312–6.

    Article  PubMed  CAS  Google Scholar 

  22. Ilias I, Sahdev A, Reznek RH, Grossman AB, Pacak K. The optimal imaging of adrenal tumours: a comparison of different methods. Endocr Relat Cancer. 2007;14:587–99.

    Article  PubMed  Google Scholar 

  23. Mottaghy FM, Reske SN. Functional imaging of neuroendocrine tumours with PET. Pituitary. 2006;9:237–42.

    Article  PubMed  CAS  Google Scholar 

  24. Brink I, Hoegerle S, Klisch J, Bley TA. Imaging of pheochromocytoma and paraganglioma. Fam Cancer. 2005;4(1):61–8.

    Article  PubMed  CAS  Google Scholar 

  25. Rosenspire KC, Haka MS, Van Dort ME, Jewett DM, Gildersleeve DL, Schwaiger M, et al. Synthesis and preliminary evaluation of 11C metahydroxyephedrine: a false neurotransmitter agent for heart neuronal imaging. J Nucl Med. 1990;31:1328–34.

    PubMed  CAS  Google Scholar 

  26. Shulkin BL, Wieland DM, Schwaiger M, Thompson NW, Francis IR, Haka MS, et al. PET scanning with hydroxyephedrine: an approach to the localization of phaeochromocytoma. J Nucl Med. 1992;33(6):1125–31.

    PubMed  CAS  Google Scholar 

  27. Trampal C, Engler H, Juhlin C, Bergström M, Långström B. Pheochromocytomas: detection with 11C hydroxyephedrine PET. Radiology. 2004;230(2):423–8.

    Article  PubMed  Google Scholar 

  28. Ilias I, Yu J, Carrasquillo JA, Chen CC, Eisenhofer G, Whatley M, et al. Superiority of 6-[18F]-fluorodopamine positron emission tomography versus [131I]-metaiodobenzylguanidine scintigraphy in the localization of metastatic pheochromocytoma. J Clin Endocrinol Metab. 2003;88:4083–7.

    Article  PubMed  CAS  Google Scholar 

  29. Ilias I, Chen CC, Carrasquillo JA, Whatley M, Ling A, Lazúrová I, et al. Comparison of 6-18F-fluorodopaime PET with I-123 metaiodobenzylguanidine and In-111 pentetreotide scintigraphy in localisation of non metastatic and metastatic phaeochromocytoma. J Nucl Med. 2008;49:1613–9.

    Article  PubMed  Google Scholar 

  30. Kaji P, Carrasquillo JA, Linehan WM, Chen CC, Eisenhofer G, Pinto PA, et al. The role of 6-[18F]fluorodopamine positron emission tomography in the localization of adrenal pheochromocytoma associated with von Hippel-Lindau syndrome. Eur J Endocrinol. 2007;156:483–7.

    Article  PubMed  CAS  Google Scholar 

  31. Morrish PK, Rakshi JS, Bailey DL, Sawle GV, Brooks DJ. Measuring the rate of progression and estimating the preclinical period of Parkinson’s disease with [18F] dopa PET. J Neurol Neurosurg Psychiatry. 1998;64:314–9.

    Article  PubMed  CAS  Google Scholar 

  32. Hoegerle S, Nitzsche E, Altehoefer C, Ghanem N, Manz T, Brink I, et al. Pheochromocytomas: detection with 18F DOPA whole body PET – initial results. Radiology. 2002;222:507–12.

    Article  PubMed  Google Scholar 

  33. Timmers H, Chen C, Carrasquillo J, Whatley M, Ling A, Havekes B, et al. Comparison of 18F-fluoro-L-DOPA, 18F-fluoro-deoxyglucose, and 18F-fluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma. J Clin Endocrinol Metab. 2009;94(12):4757–67.

    Article  PubMed  CAS  Google Scholar 

  34. Reynolds S, Lewington V. Radionuclide imaging of phaeochromocytoma and paraganglioma. Imaging. 2008;3(4):21–4.

    Google Scholar 

  35. Rufini V, Calcagni ML, Baum RP. Imaging of neuroendocrine tumours. Semin Nucl Med. 2006;36:228–47.

    Article  PubMed  Google Scholar 

  36. Ambrosini V, Rubello D, Nanni C, Al Nahhas A, Fanti S. 68Ga-DOTA-peptides versus 18F-DOPA PET for the assessment of NET patients. Nucl Med Commun. 2008;29:415–7.

    Article  PubMed  Google Scholar 

  37. Win Z, Al-Nahhas A, Towey D, Todd JF, Rubello D, Lewington V, et al. 68Ga-DOTATATE PET in neuroectodermal tumours: first experience. Nucl Med Commun. 2007;28:359–63.

    Article  PubMed  Google Scholar 

  38. Arnold R, Tautmann ME, Creutzfeldt W, Benning R, Benning M, Neuhaus C, et al. Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours. Gut. 1996;38:430–8.

    Article  PubMed  CAS  Google Scholar 

  39. Wild D, Mäcke HR, Waser B, Reubi JC, Ginj M, Rasch H. 68Ga-DOTANOC: a first compound for PET imaging with high affinity for somatostatin receptor subtypes 2 and 5. Eur J Nucl Med Mol Imaging. 2005;32:724.

    Article  PubMed  Google Scholar 

  40. Wild D, Schmitt JS, Ginj M, Mäcke HR, Bernard BF, Krenning E. DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals. Eur J Nucl Med Mol Imaging. 2003;30:1338–47.

    Article  PubMed  CAS  Google Scholar 

  41. Ginj M, Chen J, Walter MA, Eltschinger V, Reubi JC, Maecke HR. Preclinical evaluation of new and highly potent analogues of octreotide for predictive imaging and targeted radiotherapy. Clin Cancer Res. 2005;11:1136–45.

    PubMed  CAS  Google Scholar 

  42. Fanti S, Ambrosini V, Tomassetti P, Castellucci P, Montini G, Allegri V, et al. Evaluation of unusual neuroendocrine tumours by means of 68Ga-DOTA-NOC PET. Biomed Pharmacother. 2008;62:667–71.

    Article  PubMed  CAS  Google Scholar 

  43. Miederer M, Molatore S, Marinoni I, Perren A, Spitzweg C, Reder S, et al. Functional imaging of pheochromocytoma with Ga-DOTATOC and C-HED in a genetically defined rat model of multiple endocrine neoplasia. Int J Mol Imaging. 2011;2011:17532. doi:10.1155/2011/175352.

    Google Scholar 

  44. Kroiss A, Putzer D, Uprimny C, Decristoforo C, Gabriel M, Santner W, et al. Functional imaging in phaeochromocytoma and neuroblastoma with 68Ga-DOTA-Tyr 3-octreotide positron emission tomography and 123I-metaiodobenzylguanidine. Eur J Nucl Med Mol Imaging. 2011;38(5):865–73.

    Article  PubMed  CAS  Google Scholar 

  45. Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP, et al. Treatment with the radiolabeled somatostatin analog [177Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol. 2008;26:2124–30.

    Article  PubMed  CAS  Google Scholar 

  46. Frilling A, Sotiropoulos GC, Radtke A, Malago M, Bockisch A, Kuehl H, et al. The impact of 68Ga-DOTATOC positron emission tomography/computed tomography on the multimodal management of patients with neuroendocrine tumors. Ann Surg. 2010;252(5):850–6.

    Article  PubMed  Google Scholar 

  47. Win Z, Rahman L, Murrell J, Todd J, Al-Nahhas A. The possible role of 68Ga-DOTATATE PET in malignant abdominal paraganglioma. Eur J Nucl Med Mol Imaging. 2006;33(4):506.

    Article  PubMed  Google Scholar 

  48. Naji M, Zhao C, Welsh SJ, Meades R, Win Z, Ferrarese A, et al. 68Ga-DOTA-TATE PET vs. 123I-MIBG in identifying malignant neural crest tumours. Mol Imaging Biol. 2011;13(4):769–75.

    Article  PubMed  Google Scholar 

  49. Farnsworth J, Alsayed M, Zerizer I, Naji M, Meades R, Williams B. Retrospective study comparing Ga-68 DOTATATE PET with co-registered low dose CT in the detection of bone metastases in patients with neuroendocrine tumours. Nucl Med Commun. 2011;32:426. Abstract.

    Google Scholar 

  50. Putzer D, Gabriel M, Henninger B, Kendler D, Uprimny C, Dobrozemsky G, et al. Bone metastases in patients with neuroendocrine tumor: 68Ga-DOTA-Tyr3-octreotide PET in comparison to CT and bone scintigraphy. J Nucl Med. 2009;50(8):1214–21.

    Article  PubMed  Google Scholar 

Download references

Conflicts of interest

None.

Author information

Authors and Affiliations

  1. Departments of Nuclear Medicine and Radiology, Maidstone and Tunbridge Wells NHS Trust, Maidstone, UK

    Meeran Naji

  2. Department of Nuclear Medicine, Hammersmith Hospital, Imperial College NHS Trust, Du Cane Road, W12 0HS, London, UK

    Adil AL-Nahhas

Authors
  1. Meeran Naji
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Adil AL-Nahhas
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Adil AL-Nahhas.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Naji, M., AL-Nahhas, A. 68Ga-labelled peptides in the management of neuroectodermal tumours. Eur J Nucl Med Mol Imaging 39 (Suppl 1), 61–67 (2012). https://doi.org/10.1007/s00259-011-1990-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-011-1990-y

Keywords

Search

Navigation